Short answer
GeneDx Holdings Corp. (WGS) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $102M (up 17.4% year over year) with net income of −$63M.
Q1 2026 key financials · XBRL
- Revenue
- $102M
- +17.4% YoY
- Net income
- −$63M
- −869.8% YoY
- Operating margin
- -56.2%
- Gross margin
- 66.7%
- EPS (diluted)
- −$2.16
- −839.1% YoY
Source: XBRL data from the GeneDx Holdings Corp. (WGS) Q1 2026 10-Q on SEC EDGAR. USD.
GeneDx Holdings Corp. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $102.3M, up 17% YoY from $87.1M
- Diagnostic test revenue $101.3M, up 18%; whole exome/genome revenue up 27% on 34% volume growth
- Gross margin 66.7% vs 67.1% YoY; adjusted gross margin 68.5% vs 68.6%
- Cash and securities $170.7M; operating cash flow $(32.4)M vs $10.2M YoY
- $100.0M term loan funded; $31.3M Fabric Genomics impairment and reimbursement rates down 5%
Risk Factors
- No newly added risk factor identified; section repeats 2025 Form 10-K risks
- Credit agreement requires aggregate unrestricted cash of at least $50.0 million
- Debt covenant breach could accelerate all outstanding borrowings and terminate further credit commitments
- Market volatility risk from quarterly results, analyst estimates, competitive developments, and Middle East conditions
- $0.5 million executive stock issuance provided general corporate-purpose funding during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GeneDx Holdings Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.